X

Trial Profile

Phase II Clinical Study of E7389 for Advanced or Relapsed Breast Cancer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Aug 2013

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eribulin (Primary)
Indications Advanced breast cancer
Focus Adverse reactions; Registrational; Therapeutic Use

Most Recent Events

19 Aug 2013 Start and end dates of the extension trial amended as reported by ClinicalTrials.gov. Changed from Aug 2009 - Nov 2010 to Jan 2008 - Jan 2011.
19 Aug 2013 Start and end dates of the extension trial amended as reported by ClinicalTrials.gov. Changed from Aug 2009 - Nov 2010 to Jan 2008 - Jan 2011.
11 Oct 2011 Actual end date of the extension trial (NCT00965523) is Nov 2010.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com